Free Trial

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences logo
$74.39 -0.16 (-0.21%)
Closing price 03:59 PM Eastern
Extended Trading
$74.60 +0.21 (+0.28%)
As of 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
1
Hold
8
Buy
14

Based on 23 Wall Street analysts who have issued ratings for Edwards Lifesciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 1 has given a sell rating, 8 have given a hold rating, 11 have given a buy rating, and 3 have given a strong buy rating for EW.

Consensus Price Target

$87.17
17.18% Upside
According to the 23 analysts' twelve-month price targets for Edwards Lifesciences, the average price target is $87.17. The highest price target for EW is $100.00, while the lowest price target for EW is $60.00. The average price target represents a forecasted upside of 17.18% from the current price of $74.39.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for EW and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Edwards Lifesciences and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EW Analyst Ratings Over Time

TypeCurrent Forecast
9/19/24 to 9/19/25
1 Month Ago
8/20/24 to 8/20/25
3 Months Ago
6/21/24 to 6/21/25
1 Year Ago
9/20/23 to 9/19/24
Strong Buy
3 Strong Buy rating(s)
3 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
11 Buy rating(s)
12 Buy rating(s)
11 Buy rating(s)
11 Buy rating(s)
Hold
8 Hold rating(s)
10 Hold rating(s)
13 Hold rating(s)
15 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$87.17$85.90$80.20$79.82
Forecasted Upside17.18% Upside5.70% Upside8.69% Upside18.67% Upside
Consensus RatingModerate BuyModerate BuyHoldHold

EW Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EW Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Edwards Lifesciences Stock vs. The Competition

TypeEdwards LifesciencesMedical CompaniesS&P 500
Consensus Rating Score
2.70
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside17.20% Upside14,487.50% Upside11.42% Upside
News Sentiment Rating
Positive News

See Recent EW News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
8/7/2025Wells Fargo & Company
3 of 5 stars
Larry Biegelsen
1 of 5 stars
Boost TargetOverweight$84.00 ➝ $88.00+13.49%
7/29/2025Daiwa America
5 of 5 stars
 UpgradeHoldStrong-Buy
7/29/2025BTIG Research
2 of 5 stars
 UpgradeNeutralBuy$100.00+27.45%
7/25/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy
7/25/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeStrong-Buy
7/25/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$80.00 ➝ $85.00+6.36%
7/25/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetHold$75.00 ➝ $81.00+2.36%
7/25/2025Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$87.00 ➝ $95.00+20.64%
7/25/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetHold$81.00 ➝ $82.00+2.31%
7/25/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$83.00 ➝ $90.00+13.33%
7/25/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$90.00 ➝ $95.00+19.63%
7/25/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$90.00 ➝ $95.00+19.63%
7/25/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$85.00 ➝ $89.00+13.55%
7/25/2025Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetIn-Line$77.00 ➝ $80.00+0.28%
7/25/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$85.00 ➝ $94.00+24.21%
7/25/2025Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$78.00 ➝ $79.00+4.39%
7/15/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$75.00 ➝ $81.00+3.39%
7/10/2025Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
6/2/2025Dbs Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
5/22/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$84.00 ➝ $95.00+26.60%
2/12/2025Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHoldStrong Sell
12/16/2024Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeNeutralBuy$82.00 ➝ $90.00+20.97%
10/28/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong SellHold
9/18/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyHold$85.00 ➝ $70.00+4.14%
9/12/2024Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform$90.00 ➝ $90.00+34.71%
9/10/2024UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetNeutral$90.00 ➝ $75.00+12.66%
7/31/2024Daiwa Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeNeutralOutperform
7/25/2024Baird R W
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
7/25/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold$100.00 ➝ $70.00+14.27%
3/26/2024OTR Global
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeMixedPositive
10/16/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
10/16/2023Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageMarket Perform$75.00+4.90%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 06:02 PM ET.


Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 17, 2025. Please send any questions or comments about these Edwards Lifesciences pros and cons to contact@marketbeat.com.

Edwards Lifesciences
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.:

  • The current stock price is around $76, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Recent earnings reports show that the company has consistently beaten analysts' expectations, indicating strong operational performance and potential for future growth.
  • Analysts have a consensus rating of "Moderate Buy" for the stock, with multiple firms recently increasing their price targets, suggesting positive market sentiment.
  • The company has a solid market capitalization of approximately $44.68 billion, which reflects its stability and established presence in the medical technology field.
  • Edwards Lifesciences Co. has demonstrated impressive revenue growth, with a year-over-year increase of nearly 12%, showcasing its ability to expand in a competitive market.

Edwards Lifesciences
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons:

  • The stock has experienced a decline of about 1.9% recently, which may indicate short-term volatility and investor uncertainty.
  • Insider selling activity has been noted, with significant shares sold by executives, which could signal a lack of confidence in the stock's near-term performance.
  • The company has a relatively high price-to-earnings (P/E) ratio of 10.95, which may suggest that the stock is overvalued compared to its earnings potential.
  • Despite strong revenue growth, the earnings per share (EPS) guidance for the upcoming quarters indicates a potential slowdown, which could affect investor sentiment.
  • Market conditions and economic factors, such as rising interest rates, could impact the healthcare sector's performance, including Edwards Lifesciences Co.

EW Forecast - Frequently Asked Questions

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Edwards Lifesciences is $87.17, with a high forecast of $100.00 and a low forecast of $60.00.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There is currently 1 sell rating, 8 hold ratings, 11 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EW shares.

According to analysts, Edwards Lifesciences's stock has a predicted upside of 17.18% based on their 12-month stock forecasts.

Over the previous 90 days, Edwards Lifesciences's stock had 4 upgrades by analysts.

Analysts like Edwards Lifesciences less than other "medical" companies. The consensus rating score for Edwards Lifesciences is 2.70 while the average consensus rating score for "medical" companies is 2.78. Learn more on how EW compares to other companies.


This page (NYSE:EW) was last updated on 9/19/2025 by MarketBeat.com Staff
From Our Partners